Last reviewed 2026-05-22 · How we verify

Romozosumab

Amgen · Phase 3 active Small molecule ✓ Verified May 2026

Romozosumab is a Small molecule drug developed by Amgen. It is currently in Phase 3 development. Also known as: AMG 785.

Romozosumab is a medication used to treat postmenopausal osteoporosis and osteoporosis. It is administered as part of an open-label study comparing its effects to teriparatide in postmenopausal women.

Likelihood of approval

61.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
Amgen is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Romozosumab
Also known as	AMG 785
Sponsor	Amgen
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Romozosumab CI brief — competitive landscape report
Romozosumab updates RSS · CI watch RSS
Amgen portfolio CI

Frequently asked questions about Romozosumab

What is Romozosumab?

Romozosumab is a Small molecule drug developed by Amgen.

Who makes Romozosumab?

Romozosumab is developed by Amgen (see full Amgen pipeline at /company/amgen).

Is Romozosumab also known as anything else?

Romozosumab is also known as AMG 785.

What development phase is Romozosumab in?

Romozosumab is in Phase 3.

Manufacturer: Amgen — full pipeline
Therapeutic area: All drugs in Other
Also known as: AMG 785

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing